INTRODUCTION: Improving disease awareness and treatment adherence is key for the long-term management of atopic dermatitis (AD). Digital interventions can support patients in disease self-management and adopting a healthier lifestyle through behavioral modifications. We aimed to test the clinical efficacy of a digital program in patients with AD. METHODS: Adults with mild-to-severe AD were recruited for a 6-week feasibility study. The intervention was delivered through a mobile app and consisted of symptom and trigger education, treatment reminders, lifestyle coaching, and healthy lifestyle support. Here we report the secondary outcomes of intervention efficacy on clinical symptoms, as assessed by Scoring Atopic Dermatitis (SCORAD) and Patient-Oriented Eczema Measure (POEM), on health-related quality of life (HR QoL) as assessed by Dermatology Life Quality Index (DLQI), and changes in behaviors related to disease management as assessed by a six-item questionnaire. RESULTS: Twenty of 21 patients (95.2%) completed the program (81% female, mean age 31.4 years, mean time from diagnosis 26.8 years). Clinical symptoms and patient-reported global severity improved by 44% and 46%, respectively, while HR QoL improved by 41% (p < 0.001 for all measures). Adherence to treatments and preventive measures improved from pre- to post-intervention, including skincare, avoidance of triggers, and disease-related knowledge. A significant interaction was observed between increased treatment adherence and clinical improvement, such that larger clinical improvements were observed in patients with higher treatment adherence. CONCLUSION: Patients with AD are open to and can benefit from a digitally delivered targeted intervention, as demonstrated by significant improvements in treatment adherence and related clinical outcomes.
INTRODUCTION: Improving disease awareness and treatment adherence is key for the long-term management of atopic dermatitis (AD). Digital interventions can support patients in disease self-management and adopting a healthier lifestyle through behavioral modifications. We aimed to test the clinical efficacy of a digital program in patients with AD. METHODS: Adults with mild-to-severe AD were recruited for a 6-week feasibility study. The intervention was delivered through a mobile app and consisted of symptom and trigger education, treatment reminders, lifestyle coaching, and healthy lifestyle support. Here we report the secondary outcomes of intervention efficacy on clinical symptoms, as assessed by Scoring Atopic Dermatitis (SCORAD) and Patient-Oriented Eczema Measure (POEM), on health-related quality of life (HR QoL) as assessed by Dermatology Life Quality Index (DLQI), and changes in behaviors related to disease management as assessed by a six-item questionnaire. RESULTS: Twenty of 21 patients (95.2%) completed the program (81% female, mean age 31.4 years, mean time from diagnosis 26.8 years). Clinical symptoms and patient-reported global severity improved by 44% and 46%, respectively, while HR QoL improved by 41% (p < 0.001 for all measures). Adherence to treatments and preventive measures improved from pre- to post-intervention, including skincare, avoidance of triggers, and disease-related knowledge. A significant interaction was observed between increased treatment adherence and clinical improvement, such that larger clinical improvements were observed in patients with higher treatment adherence. CONCLUSION: Patients with AD are open to and can benefit from a digitally delivered targeted intervention, as demonstrated by significant improvements in treatment adherence and related clinical outcomes.
Authors: Andrea W M Evers; Piet Duller; Elke M G J de Jong; Marisol E Otero; Christianne M Verhaak; Pieter G M van der Valk; Peter C M van de Kerkhof; Floris W Kraaimaat Journal: Acta Derm Venereol Date: 2009 Impact factor: 4.437
Authors: Ville Kiiski; Alexander Salava; Päivikki Susitaival; Satu Barnhill; Anita Remitz; Markku Heliovaara Journal: Int J Dermatol Date: 2021-09-12 Impact factor: 2.736
Authors: B Björkstén; D Dumitrascu; T Foucard; N Khetsuriani; R Khaitov; M Leja; G Lis; J Pekkanen; A Priftanji; M A Riikjärv Journal: Eur Respir J Date: 1998-08 Impact factor: 16.671
Authors: Jonathan I Silverberg; Joel M Gelfand; David J Margolis; Luz Fonacier; Mark Boguniewicz; Lawrence B Schwartz; Eric Simpson; Mitchell H Grayson; Peck Y Ong; Zelma C Chiesa Fuxench Journal: Ann Allergy Asthma Immunol Date: 2018-07-09 Impact factor: 6.347
Authors: Lieneke Fm Ariens; Florine Ml Schussler-Raymakers; Cynthia Frima; Annebeth Flinterman; Eefje Hamminga; Bernd Wm Arents; Carla Afm Bruijnzeel-Koomen; Marjolein S de Bruin-Weller; Harmieke van Os-Medendorp Journal: J Med Internet Res Date: 2017-09-05 Impact factor: 5.428
Authors: Kristina M Joergensen; Christian Vestergaard; Morten S Joergensen; Aleksander Eiken; Martin Malmstedt-Miller; Anders N Ø Schultz; Mette Deleuran; John R Zibert Journal: Dermatol Res Pract Date: 2020-02-13